IDH1 and central nervous system cancer: Discovery of mutations in isocitrate dehydrogenase 1 (IDH1), which encodes a metabolic enzyme involved in the tricarboxylic acid cycle, significantly altered the trajectory of diagnostic neuropathology and laid the groundwork for the 2016 WHO classification update, particularly for lower-grade (WHO grades II and III) gliomas (105).